Viewing Study NCT00311272



Ignite Creation Date: 2024-05-05 @ 4:46 PM
Last Modification Date: 2024-10-26 @ 9:24 AM
Study NCT ID: NCT00311272
Status: COMPLETED
Last Update Posted: 2009-02-18
First Post: 2006-04-03

Brief Title: Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer
Sponsor: University Hospital Gentofte Copenhagen
Organization: University Hospital Gentofte Copenhagen

Study Overview

Official Title: Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate MelCancerVac for Treatment of Patients With Advanced Colorectal Cancer
Status: COMPLETED
Status Verified Date: 2009-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Dendritic cells loaded with tumor antigens induce cytotoxic T-cells which have been proved capable of killing both melanoma and breast cancer cells Melanoma and colorectal cancer cells express some common antigens Hence it is possible to use melanoma lysate to load the dendritic cells with tumor antigens similar to the antigens expressed by the patients colorectal cancer cells

The patient receives 10 vaccinations with 14 days between each The parameters for effect are changes in tumormetastasis size measured with computed tomography CT decrease in serum concentration of carcinoembryonic antigen CEA performance status measured by the World Health Organization WHO criteria and Quality of Life
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None